Japanese Journal of Cancer and Chemotherapy最新文献

{"title":"[A Case of Small Intestinal GIST with Small Intestinal Torsion during Follow-Up as an Ovarian Cyst].","authors":"Yukako Kushitani, Naoki Aomatsu, Takehiko Iwauchi, Keiho Aomatsu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An 87-year-old woman with no prior history of laparotomy visited her local doctor complaining of anorexia. She was diagnosed with intestinal obstruction and initially managed conservatively with fasting; however, her condition did not improve, and she was referred to our hospital on the seventh day after symptom onset. Abdominal CT revealed a 2-cm cystic lesion on the anterior surface of the sacral pelvic cavity and a whirlpool sign near the end of the ileum. Based on these findings, a diagnosis of small intestinal volvulus and an ovarian cyst-previously noted-was made, and emergency surgery was performed on the same day. Intraoperative findings showed no ovarian abnormalities; instead, a lobulated tumor with an extramural cystic growth was identified in the ileum, 210 cm proximal to the anal verge from the ligament of Treitz and 120 cm distal to the ileocecal valve. The small intestine was twisted 360 degrees in a counterclockwise direction around the tumor. There was no evidence of ischemia in the small intestine, and a partial ileal resection including the tumor was performed. Histopathological examination confirmed a diagnosis of gastrointestinal stromal tumor (GIST) of the small intestine. Small intestinal GISTs with cystic features are relatively rare, and there have been scattered reports highlighting the difficulty in differentiating them from ovarian tumors on imaging. Additionally, secondary small bowel volvulus caused by small intestinal GISTs is also uncommon. We report these 2 characteristics of small intestinal GISTs with a review of the relevant literature.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"296-298"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Unresectable Advanced Gastric Gastrointestinal Stromal Tumor (GIST) Successfully Controlled with Combined Surgical Treatment and Chemotherapy].","authors":"Masaya Kato, Satoko Sumimoto, Kentaro Kishi, Shimon Hayase, Rikimaru Yoshino, Shoko Asamoto, Satoshi Okubo, Keisuke Toya, Momoko Ichihara, Takamichi Komori, Kazuhiko Hashimoto, Mutsumi Fukunaga","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a woman in her 60s. Contrast-enhanced CT revealed a large, heterogeneously enhancing mass centered beneath the left diaphragm. A biopsy confirmed the diagnosis as gastric gastrointestinal stromal tumor (GIST), classified as cT4, N0, M1, clinical Stage Ⅳ. Treatment with imatinib at 400 mg/day was initiated. After 8 months the tumor appeared to shrink, and a PET scan was performed. The PET scan revealed localized FDG uptake in the ileocecal region only. Further investigation led to a diagnosis of colon cancer. With the possibility of resistance to treatment, surgical resection was planned together with ileo-cecal resection for colon cancer. Laparoscopy-assisted local gastrectomy, tumor resection combined splenectomy, and peritoneal nodules resection with omentectomy were performed. After surgery, patient continued imatinib again, and is alive without progression.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"284-286"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Recurrent Esophageal Cancer Treated by Salvage Surgery with a History of 90 Gy Irradiation to the Neck].","authors":"Keisuke Tanino, Hironori Kawada, Riko Zaha, Kenta Nishimura, Kosuke Kaneda, Kento Awane, Shim Yugang, Kaichirou Harada, Ryuta Nishitai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a 73-year-old man. He had upper thoracic esophageal cancer, cT3N2M0, cStage Ⅲ, and underwent definitive CRT (60 Gy + 2 courses of FP), which resulted in a CR. He was subsequently found to have early-stage mid- and hypopharyngeal cancer, and underwent radiation therapy (50 Gy). He was found to have a local recurrence, and underwent a thoracoscopic subtotal esophagectomy as a salvage procedure. The postoperative course was uneventful. Although balloon dilatation was necessary many times for anastomotic stenosis, he has been alive without recurrence for 2 years after surgery.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"305-306"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Elucidation of Natural Killer (NK) Cell Evasion Mechanisms in Colorectal Carcinogenesis Using Single-Cell RNA Sequencing and Spatial Gene Expression Analysis].","authors":"Koshi Mimori","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Natural killer (NK) cells play a critical role in antitumor immunity by rapidly eliminating stressed or transformed cells through recognition of reduced MHC classⅠexpression and upregulation of activating ligands such as MICA/B. However, accumulating evidence indicates that NK cells within the tumor microenvironment (TME) frequently exhibit functional exhaustion and impaired cytotoxicity. In this article, we review the molecular and spatial mechanisms underlying NK-cell dysfunction in colorectal tumorigenesis, with a particular focus on insights gained from single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics. Tumor-derived immunosuppressive factors, including transforming growth factor-β (TGF-β), prostaglandin E2, adenosine, and metabolic stressors such as hypoxia and nutrient deprivation, suppress NK-cell activation, cytokine production, and cytolytic function. These signals also promote the phenotypic conversion of NK cells into ILC1-like cells with reduced antitumor capacity. Spatial analyses of colorectal cancer tissues reveal a striking compartmentalization of NK-cell states. The activated NK cells expressing IFN-γ, GZMB, and PRF1 preferentially localize to tumor margins, whereas exhausted or ILC1-like NK cells predominate within tumor cores. Integrative analyses combining public scRNA-seq datasets with in-house spatial transcriptomic data demonstrate that NK cells are enriched in adenomatous lesions but are progressively excluded during the transition from adenoma to carcinoma, suggesting that NK cell evasion is an early event in colorectal cancer progression. Notably, NK cells that remain in close proximity to cancer cells retain enhanced cytotoxic and immune-activating signatures. Clinically, higher intratumoral NK-cell infiltration is significantly associated with improved overall survival, highlighting the importance of both NK-cell abundance and functional state. These findings underscore the therapeutic potential of targeting NK-cell exhaustion and reactivation. Strategies including NKG2A or TIGIT checkpoint blockade, inhibition of TGF-β signaling, metabolic reprogramming, and engineered NK-cell therapies such as CAR-NK or iPSC-derived NK cells represent promising approaches to restore NK-cell-mediated antitumor immunity in colorectal cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"244-248"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Unresectable Gastric Cancer Treated with Zolbetuximab].","authors":"Kazushi Yamashita, Yangi Mun, Daigo Nobumoto, Yasuhito Shimizu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a 78-year-old man. He had poor appetite and postprandial vomiting. The diagnosis was pyloric stenosis associated with gastric cancer. Surgery was performed, but local progression was observed and curative resection was difficult, so gastrojejunostomy and cholecystectomy were performed. Based on biomarker results, he was started on CAPOX +zolbetuximab. Chemotherapy showed a significant response. On the other hand, edema due to hypoalbuminemia was observed as a serious side effect, and administration of an albumin product was also necessary when CAPOX + zolbetuximab was administered. Zolbetuximab was launched in June 2024 as an anticancer drug useful for patients with CLDN18.2 positive and HER2 negative curatively unresectable advanced or recurrent gastric cancer. The mechanism and response to side effects such as hypoalbuminemia are still unclear, and more cases need to be accumulated.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"293-295"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Recurrent Esophagogastric Junction Cancer with Long‒Term Complete Response by Trastuzumab Deruxtecan].","authors":"Shigeyoshi Higashi, Haruna Furukawa, Shogo Yanagi, Mayu Shindo, Nobuo Takiguchi, Daishi Yoshimura, Hisataka Ogawa, Yoshiaki Omura, Masakazu Miyake, Masahiro Tanemura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 44-year-old man presented in December 2019 with a chief complaint of pericardial discomfort. Type 2 lesion at the esophagogastric junction and enlarged periaortic lymph nodes were observed. After neoadjuvant chemotherapy (docetaxel +oxaliplatin + S-1: DOS), he underwent proximal gastrectomy, double tract reconstruction and para-aortic lymph node dissection. The pathological examination showed residual para-aortic lymph node metastases, Ae, T3N1M1 (LYM) CY0P0H0, pStage Ⅳ, HER2 positive. In November 2021, the patient presented with para-aortic lymph node recurrence and was treated with S-1 + oxaliplatin (SOX) + trastuzumab (Tmab) and paclitaxel + ramucirumab, but the lymph nodes were enlarged and trastuzumab deruxtecan (T-DXd) therapy was started. After 4 courses, tumour markers normalised and para-aortic lymph nodes disappeared. After 17 courses, chemotherapy was discontinued after 1 year of complete response (CR). Sixteen months after completing chemotherapy, the patient maintained a CR. T-DXd was approved for the treatment of HER2-positive unresectable advanced or recurrent gastric cancer from the 6th edition of Gastric Cancer Treatment Guidelines. We report a case of long-term CR maintenance after T-DXd therapy for recurrent esophagogastric junction gastric cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"287-289"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Primary Breast Diffuse Large B-Cell Lymphoma in a Male Patient].","authors":"Hanae Matsuda, Masae Miyashita, Kazuo Tanaka, Yuko Kuwae, Masahiko Osawa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a 68-year-old man who presented with a progressively enlarging mass in the left breast. Breast ultrasonography revealed an irregular hypoechoic mass in region E of the left breast. A core needle biopsy (CNB) revealed diffuse large B-cell lymphoma (DLBCL). Positron emission tomography-computed tomography (PET-CT) showed no abnormal uptake in organs outside the breast, and bone marrow examination revealed no involvement. The patient was diagnosed with primary DLBCL in the breast. Surgical resection was chosen for both a definitive diagnosis and because the patient experienced pain due to the rapid enlargement of the tumor. Postoperatively, polatuzumab vedotin and R-CHP (Pola + R-CHP) were administered.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"269-271"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Long-Term Survival after Resection of Postoperative Lung Metastasis from Pancreatic Cancer].","authors":"Yoshiteru Katsura, Koji Hayashi, Narumi Sawamura, Satomi Sakai, Sakina Hashizume, Ryuta Ueda, Masahiro Koh, Yoshiki Taniguchi, Akio Hara, Naomi Urano, Hiroshi Takeyama, Setsuko Yoshioka, Hideoki Yokouchi, Kazuhiro Nishikawa, Shu Okamura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pancreatic cancer has an extremely poor prognosis due to recurrence in the early postoperative period. We report here a case of long-term survival after radical pancreatic cancer resection for lung metastasis. A 63-year-old man was found to have a pancreatic head mass during abdominal ultrasound examination due to an elevated CA19-9 level. He was referred to our department with a diagnosis of pancreatic head cancer (cStage ⅡB), and pancreatoduodenectomy was performed. The pathology results showed a diagnosis of pancreatic head cancer (pStage ⅡB), and GEM (1,000 mg/m2) was administered for 6 months (6 courses) as postoperative adjuvant therapy. Two and a half years after surgery, a nodule appeared in the lower lobe of the right lung (S10) on CT. Although the nodule had been gradually increasing, it was unclear whether it was a primary lung cancer or a lung metastasis of pancreatic cancer. A wedge resection of the lower lobe of the right lung was performed 3 years and 3 months after the initial surgery to confirm the diagnosis. The pathology results were consistent with lung metastasis of pancreatic cancer, and the patient was diagnosed as a case of recurrent pancreatic cancer. TS-1 (100 mg/day) was administered for 6 months (4 courses) as postoperative adjuvant therapy. The patient is currently under outpatient follow-up with no recurrence, 6 years and 1 month after the initial surgery and 3 years and 11 months after the recurrence surgery.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"290-292"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effectiveness of Adding Fosnetupitant to a Doublet Antiemetic Therapy Containing Palonosetron for Trastuzumab Deruxtecan-Induced Nausea and Vomiting - A Retrospective Comparative Study].","authors":"Takahiro Saito, Makoto Shinada, Rie Sato, Daichi Arai, Tsubasa Ono, Erika Kanai, Tomohito Nakazawa, Hideyuki Osawa, Michiko Harao, Yasushi Imai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The emetic risk of trastuzumab deruxtecan (T-DXd) is classified as moderate in Japan; however, controlling nausea and vomiting is difficult with doublet therapy comprising a 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist and dexamethasone. We retrospectively evaluated the effect of adding a neurokinin-1 (NK1) receptor antagonist to doublet antiemetic therapy with palonosetron and dexamethasone on T-DXd-induced nausea and vomiting. The patients were divided into those receiving triplet antiemetic therapy containing the NK1 receptor antagonist fosnetupitant (PDN group) and those receiving doublet antiemetic therapy without fosnetupitant (PD group). Adding fosnetupitant increased the complete antiemetic control rate in the PDN group by 34.9% compared with that in the PD group. Triplet antiemetic therapy with palonosetron, dexamethasone, and fosnetupitant may provide effective antiemetic prophylaxis for T-DXd-induced nausea and vo miting.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"261-264"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Interpreting the Tumor Microenvironment via Spatial Transcriptomics - Pathology Imaging and Cell-Cell Interactions].","authors":"Yukina Kusunoki, Shugo Suzuki, Kanae Echizen, Yoshiki Nonaka, Hiroaki Kasashima, Kiyoshi Maeda, Naoko Ohtani","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In recent years, spatial transcriptomics has matured as a technology that simultaneously acquires positional information on tissue sections and gene expression, enabling a re-interpretation of histomorphology (histopathology) in molecular terms. In practice, it is useful to (ⅰ) group regions by clustering, (ⅱ) overlay representative markers onto section coordinates, (ⅲ) align results with the pathology image, and (ⅳ) assess reproducibility across samples and individuals. In addition, by performing ligand-receptor-based cell-cell interaction analyses and observing, along the morphological sequence of normal →dysplasia→tumor, the emergence, increase, decrease, or loss of specific interaction axes, one can connect a spatial snapshot to information that reflects temporal change. Methodologically, sequence-based platforms, suited to surveying the global landscape, and in situ hybridization-based platforms, suited to precise reading of boundaries and neighborhood relations, may be selected and combined according to purpose; with continued advances, this integrated approach may support patient stratification and treatment selection. Taken together, viewing the tumor microenvironment through both spatial and temporal perspectives using spatial transcriptomics provides a practical framework to understand the TME as a dynamically evolving environment under continuous construction.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"255-260"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}